| Summary: |
The general aim of this project was to investigate the effects of isoform selective HDAC inhibitors upon neurophysiology and test their therapeutic potential in disease models. More specifically, we aimed to test the hypothesis that HDAC1 or HDAC6 inhibitors modulate neurodevelopment, as well as intracellular dynamics such as that of mitochondria and autophagosomes. For the disease contexts, we aimed to assess the effects of HDAC inhibitors in models of Huntington's disease (in vitro: primary neurons), Parkinson's disease (in vivo: zebrafish) and Myasthenia gravis (in vivo: rat). In doing so, we aimed to address open questions concerning the advantages and disadvantages of inhibiting specific HDAC isoforms in these different contexts, hoping to advance this field of knowledge. Additional aims of this project were to publish our findings in international journals, present them in national and international meetings, and also to organize scientific events. Further, we aimed to foster the development of young scientists, not only the PhD students involved in the Project, but also to recruit and provide advanced training opportunities for young people wanting to progress as scientists. |